Frequent hemorrhagic lesions in cerebral toxoplasmosis in AIDS patients

• Published in: Journal of neuroimaging Vol. 19; no. 2; p. 169
• Main Authors: Bhagavati, Satyakam, Choi, Jan
• Format: Journal Article
• Language: English
• Published: United States 01.04.2009
• Subjects: Adult; AIDS-Related Opportunistic Infections - complications; AIDS-Related Opportunistic Infections - diagnostic imaging; AIDS-Related Opportunistic Infections - pathology; Animals; Brain - diagnostic imaging; Brain - pathology; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Intracranial Hemorrhages - diagnostic imaging; Intracranial Hemorrhages - etiology; Intracranial Hemorrhages - pathology; Intracranial Hemorrhages - therapy; Magnetic Resonance Imaging; Male; Middle Aged; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral - complications; Toxoplasmosis, Cerebral - diagnostic imaging; Toxoplasmosis, Cerebral - pathology; Toxoplasmosis, Cerebral - therapy; Treatment Outcome
• ISSN: 1552-6569
• DOI: 10.1111/j.1552-6569.2008.00274.x

Cerebral toxoplasmosis is a frequent complication in immunosuppressed patients such as AIDS (acquired immunodeficiency syndrome). Frequently, lesions are located deep in the brain which are inaccessible for biopsy making rapid diagnosis dependent on accurate interpretation of neuroimaging findings. The commonest cranial CT findings reported in toxoplasmosis are ring enhancing hypodense lesions in basal ganglia or cortical gray matter. Hemorrhage has only rarely been described and is usually seen following antitoxoplasma treatment. We reviewed the records of 11 AIDS patients with cerebral toxoplasmosis and found multiple hemorrhagic cerebral, cerebellar, or brain stem lesions in 7 of 11 patients. Six patients had hemorrhage at the time of initial clinical presentation and one developed hemorrhage following 2 weeks of antitoxoplasma treatment. We conclude that hemorrhagic lesions are frequently found on cranial MRI scans in cerebral toxoplasmosis. AIDS patients presenting with hemorrhagic cerebral lesions should be considered for a trial of presumptive antitoxoplasma treatment.